The Living Guidelines: UA/NSTEMI Recommendations for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy Polling Results for CLASS IIa Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class IIa Guidelines
1. For UA/NSTEMI patients in whom PCI is selected as a post angiography management strategy, it is reasonable to omit administration of an intravenous GP IIb/IIIa antagonist if bivalirudin was selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 h earlier. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class IIa Recommendation 1 for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy should be: CLASS I CLASS IIa CLASS IIb CLASS III

2. If Left Ventricular Ejection Fraction is ≤40%, it is reasonable to perform diagnostic angiography. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class IIa Recommendation 2 for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy should be: CLASS I CLASS IIa CLASS IIb CLASS III

3. If Left Ventricular Ejection Fraction is >40%, it is reasonable to perform a stress test. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class IIa Recommendation 3 for Additional Management Considerations for Antiplatelet and Anticoagulant Therapy should be: CLASS I CLASS IIa CLASS IIb CLASS III